248 studies found for:    "Transitional cell carcinoma"
Show Display Options
Rank Status Study
1 Active, not recruiting Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma
Condition: Transitional Cell Carcinoma
Intervention: Drug: Erlotinib Hydrochloride
2 Recruiting Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel
Condition: Transitional Cell Carcinoma
Interventions: Drug: Cabazitaxel;   Other: Best Supportive Care
3 Unknown  JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
Condition: Bladder Transitional Cell Carcinoma Stage IV
Interventions: Drug: Vinflunine, Gemcitabine;   Drug: Vinflunine, Carboplatin
4 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
5 Active, not recruiting Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
Conditions: Recurrent Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Biological: Trastuzumab;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin
6 Completed Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Conditions: Transitional Cell Carcinoma;   Bladder Neoplasms;   Kidney Neoplasms;   Ureter Neoplasms;   Bladder Cancer;   Neoplasm, Bladder
Intervention: Drug: vinflunine
7 Terminated Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
Conditions: Recurrent Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Drug: docetaxel;   Drug: lapatinib ditosylate;   Other: immunohistochemistry staining method;   Genetic: fluorescence in situ hybridization;   Other: laboratory biomarker analysis
8 Completed Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
Condition: Transitional Cell Carcinoma of the Bladder
Interventions: Drug: Dasatinib;   Procedure: Radical Cystectomy
9 Active, not recruiting Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Conditions: Bladder Cancer;   Metastatic Transitional Cell Carcinoma
Intervention: Drug: Everolimus
10 Completed Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Bladder Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage III Bladder Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer
Intervention: Drug: bortezomib
11 Recruiting Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Condition: Metastatic Transitional Cell Carcinoma of the Urothelium
Intervention: Drug: Buparlisib
12 Recruiting Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Condition: Urothelium Transitional Cell Carcinoma
Interventions: Drug: Cabazitaxel;   Drug: Vinflunine
13 Completed Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Conditions: Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: vinblastine sulfate;   Drug: methotrexate;   Drug: cisplatin;   Biological: filgrastim
14 Active, not recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02;   Other: Standard of Care
15 Suspended Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Drug: Docetaxel;   Drug: ASA404
16 Withdrawn Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Drug: AMG 386;   Drug: Docetaxel
17 Completed Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
Conditions: Transitional Cell Carcinoma of the Urothelial Tract;   Bladder Cancer;   Bladder Neoplasms
Intervention: Drug: vinflunine and best supportive care
18 Active, not recruiting Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Condition: Urothelial Carcinoma
Interventions: Drug: Cabazitaxel;   Drug: Neulasta;   Procedure: CT Scan;   Biological: Blood Draw
19 Unknown  Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma
Condition: Urothelial Carcinoma
Intervention:
20 Not yet recruiting EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells
Condition: Urothelial Carcinoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years